LipoBIND - Fat blocker made from natural dried cactus extract. While reducing fat intake is certainly associated with dieting, it is also among the goals of those with perfectly healthy weights who take LipoBIND. Fat is one of the more dangerous elements of food and, though our bodies require a certain amount of it to function correctly, the amounts contained in many of the most popular dishes are far in excess of what's needed and what's healthy. Reducing this fat intake can have significant effects on one's overall health and, fortunately, this goal can be accomplished with the use of entirely natural ingredients which are safe for the vast majority of individuals.
LipoBIND is made out of cactus leaves. The substances contained in these leaves bind with fat. When the two merge, they create a sort of gel of dietary fiber and fat which is passed harmlessly from the body along with any other waste. This can reduce the amount of fat that one receives from their food by as much as 27 percent, according to the manufacturer's literature. There are other ways in which LipoBIND is designed to make losing weight easier and more convenient than it tends to be otherwise.
LipoBIND helps to control one's appetite. Most appetite problems are caused by sharp peaks and valleys in one's blood glucose levels. When the levels plummet, the body will demand food and this can make it exceedingly difficult for one to stick to their diet program. LipoBIND helps keep the body's glucose levels regular which allows individuals to enjoy the sensation of being satisfied by a meal for longer and reduces the risk of one indulging a bit too much when they become hungry and, thus, ruining all the work they put toward reducing their weight in the first place.
It is recommended that one takes a vitamin supplement along with LipoBIND. The company offers its own line of supplements to go along with their LipoBIND product. Because the substances in the supplement will bind with the vitamin, it's not recommended to take a dosage of LipoBIND for 2 hours after having taken one's vitamins. This supplement is taken after meals when the materials in LipoBIND can bind with what food is in the stomach and ensure that the total amount of fat intake is not absorbed by the body. This also helps the body digest more slowly, reducing further the rate at which hunger returns.
LipoBIND is used by some individuals as a means of maintaining their already healthy weight as well as by those who need to lose weight in the short term. When it's used as a preventative supplement, the dosages are a bit different and all of this information is detailed on the manufacturer's literature. There are ceiling amounts which should be taken in the course of a day and one should adhere to these recommendations to ensure the best results and to ensure their overall health. This supplement is not recommended for those who are currently pregnant or nursing.
more info at Weight Loss. True Story Blog
FDA Advises Public of Serious Adverse Event with Psoriasis Drug Raptiva
The U.S. Food and Drug Administration today issued a public health advisory concerning three confirmed, and one possible report of progressive multifocal leukoencephalopathy (PML), a rare brain infection, in patients using the psoriasis drug Raptiva (efalizumab). Three of those patients have died. All four patients were treated with the drug for more than three years. None of the patients were receiving other treatments that suppress the immune system.
The FDA is reviewing this latest information. The agency will take appropriate steps to:
- ensure that the risks of Raptiva do not outweigh its benefits;
- that patients prescribed Raptiva are clearly informed of the signs and symptoms of PML; and
- that health care professionals carefully monitor patients for the possible development of PML.
PML is caused by a virus that affects the central nervous system. PML usually occurs in people whose immune systems have been severely weakened. It leads to an irreversible decline in neurologic function and death. Symptoms may include unusual weakness, loss of coordination, changes in vision, difficulty speaking and personality changes. There is no known effective prevention or treatment.
Psoriasis is a chronic disease, for which a number of effective therapeutic options are available, including four other approved biologic agents, ultraviolent light therapy, and the drugs cyclosporine, acitretin, and methotrexate. Generally, treatment for psoriasis patients involves a rotation of therapies.
In October 2008, the product labeling for Raptiva was revised to highlight in a boxed warning the risks of life-threatening infections, including PML. At that time, the FDA directed Genentech, the manufacturer, to develop a risk evaluation and mitigation strategy (REMS) to include a medication guide to educate patients about the drug’s risks.
The FDA strongly recommends that health care professionals carefully monitor patients on Raptiva, as well as those who have discontinued the drug, for any signs or symptoms of neurologic disease, and that they periodically reassess the benefits of continued treatment. Patients should be aware of the symptoms of PML and contact their health care professionals immediately if they experience any such symptoms.
Raptiva is a once-weekly injection approved for adults with moderate to severe plaque psoriasis who are candidates for systemic (whole body) therapy or phototherapy. The drug works by suppressing T-cells (blood cells that help fight infection) in the immune system. These cells, when activated, migrate to the skin and cause inflammation which results in the red, inflamed and scaly patches of skin, which is associated with psoriasis. By suppressing T-cells, Raptiva decreases the function of the immune system which increases a patient’s susceptibility to infections.
Health care professionals and consumers may report serious adverse events (side effects) or product quality problems with the use of this product to the FDA's MedWatch Adverse Event Reporting program online, by regular mail, fax or phone.
--Regular Mail: use postage-paid FDA form 3500 available at: www.fda.gov/MedWatch/getforms.htm and mail to MedWatch, 5600 Fishers Lane, Rockville, MD 20852-9787
--Fax: (800) FDA-0178
--Phone: (800) FDA-1088
Read the FDA’s 2009 Public Health Advisory